Am J Obstet Gynecol:米索前列醇诱导分娩:单剂量vs多剂量

2018-06-29 王淳 环球医学

2018年1月,发表在《Am J Obstet Gynecol》的一项由美国学者进行的随机对照试验,比较了单剂量vs多剂量米索前列醇诱导的阴道分娩率。

2018年1月,发表在《Am J Obstet Gynecol》的一项由美国学者进行的随机对照试验,比较了单剂量vs多剂量米索前列醇诱导的阴道分娩率。

背景:米索前列醇是一种用于促宫颈成熟和诱导分娩的常用药物,然而尚无明确证据表明实现较高阴道分娩率所需的最佳给药次数。

目的:首要目的为比较单剂量和多剂量米索前列醇方案诱导分娩后24小时内的阴道分娩率。

研究设计:2016年3月~2017年3月进行了一项随机对照试验,比较了单剂量vs 多剂量(最多可达4剂量)米索前列醇用于诱导分娩的24小时内的阴道分娩率。采用分层随机化法。入组标准为,单胎妊娠,妊娠≥37周,具有完成阴道分娩的完整胎膜条件,Bishop评分≤6,入院诱导分娩。首要结局为24小时内阴道分娩率。次要结局包括阴道分娩时间、剖宫产率、产妇和新生儿发病率。基于80%的效力、α=0.05、假设50%的多剂量米索前列醇组女性可在24小时内阴道分娩,理论上需要纳入220名患者以实现相对于单剂量组24小时内阴道分娩率增加20%。使用Mann-Whitney检验实现连续变量的比较。使用Fisher精确检验检测分类变量。P<0.05认为具有统计学意义。

结果:250名女性随机分组。组间人口统计学和临床特征相似。单变量分析中,单剂量组和多剂量组24小时内阴道分娩率无差异(41.7% vs 44.7%;P=0.698),阴道分娩时间无差异(1187 vs 1321 min,P=0.202)。单剂量组剖宫产率较高(35.8% vs 22.8%;P=0.034)。控制了初始催产素前的Bishop评分、之前妊娠情况、孕龄、BMI、胎儿估计体重、人工破膜<6cm、Foley球囊植入等变量后,泊松回归结果表明,单剂量组与剖宫产率增加不再相关。反而,初始给药前Bishop评分<4和初次分娩与剖宫产率增加显着相关。

结论:在这项首次比较单剂量和多剂量米索前列醇的随机对照试验中,单剂量方案是诱导分娩的可接受的替代方案,尤其对于经产妇和首次给药后Bishop评分>4的患者。

原始出处:

Pimentel VM, Arabkhazaeli M, Moon JY, et al. Induction of labor using one dose vs multiple doses of misoprostol: a randomized controlled trial. Am J Obstet Gynecol. 2018 Jun;218(6):614.e1-614.e8. doi: 10.1016/j.ajog.2018.03.034. Epub 2018 Mar 31.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1934069, encodeId=75a8193406918, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Nov 29 22:51:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011381, encodeId=4dd62011381b8, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Sep 01 18:51:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044055, encodeId=819420440550b, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 06 02:51:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275150, encodeId=615712e5150d1, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sun Jul 01 02:51:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1934069, encodeId=75a8193406918, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Nov 29 22:51:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011381, encodeId=4dd62011381b8, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Sep 01 18:51:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044055, encodeId=819420440550b, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 06 02:51:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275150, encodeId=615712e5150d1, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sun Jul 01 02:51:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-09-01 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=1934069, encodeId=75a8193406918, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Nov 29 22:51:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011381, encodeId=4dd62011381b8, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Sep 01 18:51:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044055, encodeId=819420440550b, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 06 02:51:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275150, encodeId=615712e5150d1, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sun Jul 01 02:51:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1934069, encodeId=75a8193406918, content=<a href='/topic/show?id=116ee610561' target=_blank style='color:#2F92EE;'>#米索前列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76105, encryptionId=116ee610561, topicName=米索前列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Nov 29 22:51:00 CST 2018, time=2018-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011381, encodeId=4dd62011381b8, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sat Sep 01 18:51:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044055, encodeId=819420440550b, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon May 06 02:51:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275150, encodeId=615712e5150d1, content=<a href='/topic/show?id=263031541b4' target=_blank style='color:#2F92EE;'>#分娩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31541, encryptionId=263031541b4, topicName=分娩)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sun Jul 01 02:51:00 CST 2018, time=2018-07-01, status=1, ipAttribution=)]
    2018-07-01 linlin2312

相关资讯

同时服用米索前列醇与非甾体抗炎药可以减少心血管疾病的风险

根据一项研究计划提交的研究,针对胃肠溃的疡药,将米索前列醇与非甾体抗炎药(NSAID)共同服用的患者比单独服用NSAIDs的患者具有显着降低严重心血管、中风和肾衰竭的风险。

Obstet Gynecol:催产素联合米索前列醇能减少产后出血吗?

由此可见,米索前列醇联合预防性常规催产素使用并没有降低产后出血风险率,反而提高了产妇不良事件的发生率。

Hum Reprod:早期流产:米索前列醇单次给药or多次给药?

2017年6月,发表在《Hum Reprod》的一项由以色列科学家进行的随机临床试验,比较了米索前列醇单次给药和多次给药用于早期终止妊娠的效果。

Lancet:米索前列醇用于子痫前期以及高血压产妇催产

子痫前期以及高血压产妇,口服米索前列醇是有效的催产方法

Am J Obstet Gynecol:诱导分娩:米索前列醇溶液该怎么使用

这些年已经积累了支持口服米索前列醇作为安全且廉价的药物用于诱导分娩的证据。2017年4月,发表在《Am J Obstet Gynecol》的一项由沙特阿拉伯科学家进行的研究,比较了每小时滴定和每2小时静口服米索前列醇溶液诱导生产的有效性和安全性。背景:米索前列醇是一种诱导分娩的有效药物。现有的指南推荐每2小时口服米索前列醇溶液25 μg。然而,需要更多研究以优化口服米索前列醇溶液用于诱导分娩。目的

Lancet Gastroen Hepatol:米索前列醇治疗非甾体抗炎药导致的小肠溃疡和糜烂

研究认为,米索前列醇可有效治疗小剂量阿司匹林和非甾体抗炎药导致的小肠溃疡和糜烂